Preliminary Final Report
Filed with ASX · · 19 pages · English
Earlier from Anagenics
- Cleansing Notice and Appendix 3B
- Cellmid Share Purchase Plan
- Cellmid Share Placement Raises $9M
- Cellmid updates on distribution of evolis
- Cellmid to commence selling of evolis into Chinese market
Later from Anagenics
- Evolis USA Distribution Update
- Cellmid Share Purchase Plan Completion
- Lead Antibody Effective in Rare Chronic Kidney Disease
- Change of Registry Address: Automic P/L - Sydney Office
- Cellmids Evolis Successfully Launched in USA stores
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics